Annual EBIT
$4.42 B
+$136.70 M+3.19%
31 December 2023
Summary:
Vertex Pharmaceuticals Incorporated annual earnings before interest & taxes is currently $4.42 billion, with the most recent change of +$136.70 million (+3.19%) on 31 December 2023. During the last 3 years, it has risen by +$1.25 billion (+39.33%). VRTX annual EBIT is now at all-time high.VRTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$1.23 B
+$4.61 B+136.42%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated quarterly earnings before interest & taxes is currently $1.23 billion, with the most recent change of +$4.61 billion (+136.42%) on 30 September 2024. Over the past year, it has increased by +$41.50 million (+3.49%). VRTX quarterly EBIT is now -4.49% below its all-time high of $1.29 billion, reached on 31 March 2024.VRTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
$298.00 M
+$41.50 M+16.18%
30 September 2024
Summary:
Vertex Pharmaceuticals Incorporated TTM earnings before interest & taxes is currently $298.00 million, with the most recent change of +$41.50 million (+16.18%) on 30 September 2024. Over the past year, it has dropped by -$4.06 billion (-93.16%). VRTX TTM EBIT is now -93.81% below its all-time high of $4.81 billion, reached on 31 March 2024.VRTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRTX EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.2% | +3.5% | -93.2% |
| 3 y3 years | +39.3% | +12.2% | -89.4% |
| 5 y5 years | +557.6% | +1345.3% | -63.4% |
VRTX EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +58.5% | -4.5% | +136.4% | -93.8% | +16.2% |
| 5 y | 5 years | at high | +557.6% | -4.5% | +136.4% | -93.8% | +16.2% |
| alltime | all time | at high | +701.6% | -4.5% | +136.4% | -93.8% | +140.4% |
Vertex Pharmaceuticals Incorporated EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.23 B(-136.4%) | $298.00 M(+16.2%) |
| June 2024 | - | -$3.38 B(-362.2%) | $256.50 M(-94.7%) |
| Mar 2024 | - | $1.29 B(+11.3%) | $4.81 B(+8.7%) |
| Dec 2023 | $4.42 B(+3.2%) | $1.16 B(-2.7%) | $4.42 B(+1.6%) |
| Sept 2023 | - | $1.19 B(+1.5%) | $4.35 B(0.0%) |
| June 2023 | - | $1.17 B(+29.9%) | $4.35 B(+3.2%) |
| Mar 2023 | - | $902.90 M(-17.0%) | $4.22 B(-1.6%) |
| Dec 2022 | $4.29 B(+53.6%) | $1.09 B(-8.5%) | $4.29 B(+5.0%) |
| Sept 2022 | - | $1.19 B(+14.5%) | $4.08 B(+2.3%) |
| June 2022 | - | $1.04 B(+7.1%) | $3.99 B(+36.5%) |
| Mar 2022 | - | $969.70 M(+9.4%) | $2.92 B(+4.8%) |
| Dec 2021 | $2.79 B(-12.1%) | $886.00 M(-19.3%) | $2.79 B(-0.7%) |
| Sept 2021 | - | $1.10 B(-3925.8%) | $2.81 B(+13.7%) |
| June 2021 | - | -$28.70 M(-103.4%) | $2.47 B(-26.0%) |
| Mar 2021 | - | $836.60 M(-7.6%) | $3.34 B(+5.2%) |
| Dec 2020 | $3.18 B(+118.5%) | $905.06 M(+19.1%) | $3.18 B(+7.2%) |
| Sept 2020 | - | $759.73 M(-9.4%) | $2.96 B(+29.5%) |
| June 2020 | - | $838.64 M(+24.9%) | $2.29 B(+27.7%) |
| Mar 2020 | - | $671.67 M(-2.8%) | $1.79 B(+23.2%) |
| Dec 2019 | $1.45 B(+116.1%) | $691.18 M(+711.1%) | $1.45 B(+78.7%) |
| Sept 2019 | - | $85.21 M(-75.1%) | $813.46 M(-7.9%) |
| June 2019 | - | $341.98 M(+2.1%) | $883.45 M(+13.8%) |
| Mar 2019 | - | $335.03 M(+553.8%) | $776.22 M(+15.4%) |
| Dec 2018 | $672.71 M(+1154.8%) | $51.24 M(-67.0%) | $672.71 M(-11.3%) |
| Sept 2018 | - | $155.20 M(-33.9%) | $758.21 M(+280.2%) |
| June 2018 | - | $234.75 M(+1.4%) | $199.41 M(+1243.9%) |
| Mar 2018 | - | $231.53 M(+69.3%) | $14.84 M(-72.3%) |
| Dec 2017 | $53.61 M(+281.1%) | $136.74 M(-133.9%) | $53.61 M(-226.5%) |
| Sept 2017 | - | -$403.60 M(-904.5%) | -$42.38 M(-112.4%) |
| June 2017 | - | $50.17 M(-81.4%) | $342.32 M(+16.3%) |
| Mar 2017 | - | $270.30 M(+563.4%) | $294.28 M(+1992.2%) |
| Dec 2016 | $14.07 M(-103.0%) | $40.74 M(-315.7%) | $14.07 M(-117.1%) |
| Sept 2016 | - | -$18.89 M(-985.4%) | -$82.07 M(-39.0%) |
| June 2016 | - | $2.13 M(-121.5%) | -$134.53 M(-56.1%) |
| Mar 2016 | - | -$9.92 M(-82.1%) | -$306.42 M(-35.3%) |
| Dec 2015 | -$473.59 M(-28.5%) | -$55.39 M(-22.4%) | -$473.59 M(-17.7%) |
| Sept 2015 | - | -$71.35 M(-58.0%) | -$575.62 M(-11.5%) |
| June 2015 | - | -$169.75 M(-4.1%) | -$650.46 M(+4.3%) |
| Mar 2015 | - | -$177.10 M(+12.5%) | -$623.52 M(-5.8%) |
| Dec 2014 | -$662.01 M(+9.8%) | -$157.42 M(+7.7%) | -$662.01 M(+29.5%) |
| Sept 2014 | - | -$146.19 M(+2.4%) | -$511.35 M(+5.7%) |
| June 2014 | - | -$142.81 M(-33.8%) | -$483.96 M(+21.6%) |
| Mar 2014 | - | -$215.59 M(+3093.5%) | -$398.11 M(-36.0%) |
| Dec 2013 | -$603.12 M(-1382.2%) | -$6.75 M(-94.3%) | -$621.99 M(-4.3%) |
| Sept 2013 | - | -$118.81 M(+108.6%) | -$649.66 M(+22.3%) |
| June 2013 | - | -$56.96 M(-87.0%) | -$531.23 M(+9.7%) |
| Mar 2013 | - | -$439.48 M(+1176.7%) | -$484.45 M(-1130.0%) |
| Dec 2012 | $47.04 M(-52.1%) | -$34.42 M(+9079.2%) | $47.03 M(-84.5%) |
| Sept 2012 | - | -$375.00 K(-96.3%) | $303.92 M(-40.6%) |
| June 2012 | - | -$10.18 M(-111.1%) | $511.96 M(+44.5%) |
| Mar 2012 | - | $92.01 M(-58.6%) | $354.23 M(+261.0%) |
| Dec 2011 | $98.13 M(-113.3%) | $222.46 M(+7.1%) | $98.13 M(-133.0%) |
| Sept 2011 | - | $207.67 M(-223.7%) | -$297.04 M(-58.1%) |
| June 2011 | - | -$167.91 M(+2.3%) | -$709.72 M(-3.8%) |
| Mar 2011 | - | -$164.09 M(-5.0%) | -$738.13 M(+0.6%) |
| Dec 2010 | -$735.35 M(+16.9%) | -$172.71 M(-15.8%) | -$733.54 M(-0.1%) |
| Sept 2010 | - | -$205.01 M(+4.4%) | -$734.60 M(+8.5%) |
| June 2010 | - | -$196.32 M(+23.1%) | -$677.05 M(+6.3%) |
| Mar 2010 | - | -$159.50 M(-8.2%) | -$636.79 M(+1.2%) |
| Dec 2009 | -$628.99 M(+37.2%) | -$173.77 M(+17.8%) | -$628.99 M(+5.6%) |
| Sept 2009 | - | -$147.46 M(-5.5%) | -$595.44 M(+3.1%) |
| June 2009 | - | -$156.06 M(+2.9%) | -$577.72 M(+12.8%) |
| Mar 2009 | - | -$151.70 M(+8.2%) | -$511.98 M(+11.7%) |
| Dec 2008 | -$458.38 M(+11.1%) | -$140.22 M(+8.1%) | -$458.38 M(+11.9%) |
| Sept 2008 | - | -$129.74 M(+43.7%) | -$409.63 M(+4.3%) |
| June 2008 | - | -$90.31 M(-7.9%) | -$392.80 M(-8.1%) |
| Mar 2008 | - | -$98.11 M(+7.3%) | -$427.20 M(+3.5%) |
| Dec 2007 | -$412.67 M | -$91.47 M(-19.0%) | -$412.67 M(+16.2%) |
| Sept 2007 | - | -$112.91 M(-9.5%) | -$355.11 M(+17.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | -$124.71 M(+49.2%) | -$302.91 M(+17.9%) |
| Mar 2007 | - | -$83.57 M(+146.5%) | -$256.97 M(+14.0%) |
| Dec 2006 | -$225.39 M(+59.0%) | -$33.91 M(-44.2%) | -$225.39 M(+6.6%) |
| Sept 2006 | - | -$60.71 M(-22.9%) | -$211.48 M(+10.3%) |
| June 2006 | - | -$78.78 M(+51.5%) | -$191.68 M(+25.1%) |
| Mar 2006 | - | -$51.99 M(+160.0%) | -$153.24 M(+8.1%) |
| Dec 2005 | -$141.74 M(+3.3%) | -$20.00 M(-51.1%) | -$141.74 M(-5.4%) |
| Sept 2005 | - | -$40.92 M(+1.4%) | -$149.82 M(+4.8%) |
| June 2005 | - | -$40.34 M(-0.4%) | -$142.93 M(-0.0%) |
| Mar 2005 | - | -$40.49 M(+44.2%) | -$142.99 M(+4.2%) |
| Dec 2004 | -$137.23 M(-20.5%) | -$28.08 M(-17.5%) | -$137.23 M(-7.0%) |
| Sept 2004 | - | -$34.03 M(-15.8%) | -$147.56 M(-6.4%) |
| June 2004 | - | -$40.40 M(+16.3%) | -$157.57 M(-23.6%) |
| Mar 2004 | - | -$34.73 M(-9.6%) | -$206.18 M(+35.4%) |
| Dec 2003 | -$172.70 M(+16.7%) | -$38.41 M(-12.8%) | -$152.24 M(-13.4%) |
| Sept 2003 | - | -$44.04 M(-50.5%) | -$175.86 M(+4.9%) |
| June 2003 | - | -$89.01 M(-563.4%) | -$167.67 M(+63.3%) |
| Mar 2003 | - | $19.21 M(-131.0%) | -$102.69 M(-30.6%) |
| Dec 2002 | -$147.96 M(+28.5%) | -$62.02 M(+73.0%) | -$147.96 M(+1.3%) |
| Sept 2002 | - | -$35.85 M(+49.2%) | -$146.06 M(+11.8%) |
| June 2002 | - | -$24.03 M(-7.8%) | -$130.61 M(+5.3%) |
| Mar 2002 | - | -$26.06 M(-56.6%) | -$124.03 M(+9.4%) |
| Dec 2001 | -$115.10 M(+207.4%) | -$60.12 M(+194.7%) | -$113.36 M(+70.7%) |
| Sept 2001 | - | -$20.40 M(+16.9%) | -$66.41 M(+8.5%) |
| June 2001 | - | -$17.45 M(+13.3%) | -$61.18 M(+78.5%) |
| Mar 2001 | - | -$15.39 M(+17.0%) | -$34.28 M(-6.9%) |
| Dec 2000 | -$37.44 M(-26.0%) | -$13.16 M(-13.2%) | -$36.80 M(+51.8%) |
| Sept 2000 | - | -$15.17 M(-260.5%) | -$24.25 M(-4.4%) |
| June 2000 | - | $9.45 M(-152.7%) | -$25.37 M(-47.1%) |
| Mar 2000 | - | -$17.92 M(+2867.1%) | -$48.00 M(-4.9%) |
| Dec 1999 | -$50.60 M(+5.9%) | -$604.00 K(-96.3%) | -$50.48 M(-34.9%) |
| Sept 1999 | - | -$16.30 M(+23.7%) | -$77.58 M(+22.4%) |
| June 1999 | - | -$13.18 M(-35.4%) | -$63.38 M(+6.0%) |
| Mar 1999 | - | -$20.40 M(-26.4%) | -$59.80 M(+15.7%) |
| Dec 1998 | -$47.80 M(+149.0%) | -$27.70 M(+1219.0%) | -$51.70 M(+69.5%) |
| Sept 1998 | - | -$2.10 M(-78.1%) | -$30.50 M(-10.6%) |
| June 1998 | - | -$9.60 M(-22.0%) | -$34.10 M(+32.7%) |
| Mar 1998 | - | -$12.30 M(+89.2%) | -$25.70 M(+35.3%) |
| Dec 1997 | -$19.20 M(-51.4%) | -$6.50 M(+14.0%) | -$19.00 M(-31.4%) |
| Sept 1997 | - | -$5.70 M(+375.0%) | -$27.70 M(-5.8%) |
| June 1997 | - | -$1.20 M(-78.6%) | -$29.40 M(-19.5%) |
| Mar 1997 | - | -$5.60 M(-63.2%) | -$36.50 M(-7.6%) |
| Dec 1996 | -$39.50 M(+49.1%) | -$15.20 M(+105.4%) | -$39.50 M(+48.5%) |
| Sept 1996 | - | -$7.40 M(-10.8%) | -$26.60 M(-2.2%) |
| June 1996 | - | -$8.30 M(-3.5%) | -$27.20 M(-6.8%) |
| Mar 1996 | - | -$8.60 M(+273.9%) | -$29.20 M(+10.2%) |
| Dec 1995 | -$26.50 M(+28.0%) | -$2.30 M(-71.3%) | -$26.50 M(-18.7%) |
| Sept 1995 | - | -$8.00 M(-22.3%) | -$32.60 M(+14.8%) |
| June 1995 | - | -$10.30 M(+74.6%) | -$28.40 M(+20.9%) |
| Mar 1995 | - | -$5.90 M(-29.8%) | -$23.50 M(+13.0%) |
| Dec 1994 | -$20.70 M(-1825.0%) | -$8.40 M(+121.1%) | -$20.80 M(+447.4%) |
| Sept 1994 | - | -$3.80 M(-29.6%) | -$3.80 M(+31.0%) |
| June 1994 | - | -$5.40 M(+68.8%) | -$2.90 M(-293.3%) |
| Mar 1994 | - | -$3.20 M(-137.2%) | $1.50 M(+25.0%) |
| Dec 1993 | $1.20 M(-112.0%) | $8.60 M(-396.6%) | $1.20 M(-111.7%) |
| Sept 1993 | - | -$2.90 M(+190.0%) | -$10.30 M(+3.0%) |
| June 1993 | - | -$1.00 M(-71.4%) | -$10.00 M(-11.5%) |
| Mar 1993 | - | -$3.50 M(+20.7%) | -$11.30 M(+14.1%) |
| Dec 1992 | -$10.00 M(+78.6%) | -$2.90 M(+11.5%) | -$9.90 M(+13.8%) |
| Sept 1992 | - | -$2.60 M(+13.0%) | -$8.70 M(+16.0%) |
| June 1992 | - | -$2.30 M(+9.5%) | -$7.50 M(+15.4%) |
| Mar 1992 | - | -$2.10 M(+23.5%) | -$6.50 M(+80.6%) |
| Dec 1991 | -$5.60 M(+36.6%) | -$1.70 M(+21.4%) | -$3.60 M(-53.2%) |
| Sept 1991 | - | -$1.40 M(+7.7%) | -$7.70 M(+35.1%) |
| June 1991 | - | -$1.30 M(-262.5%) | -$5.70 M(+50.0%) |
| Mar 1991 | - | $800.00 K(-113.8%) | -$3.80 M(-7.3%) |
| Dec 1990 | -$4.10 M | -$5.80 M(-1066.7%) | -$4.10 M(-341.2%) |
| Sept 1990 | - | $600.00 K(0.0%) | $1.70 M(+54.5%) |
| June 1990 | - | $600.00 K(+20.0%) | $1.10 M(+120.0%) |
| Mar 1990 | - | $500.00 K | $500.00 K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual earnings before interest & taxes?
- What is the all time high annual EBIT for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual EBIT year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly EBIT year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM EBIT year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual earnings before interest & taxes?
The current annual EBIT of VRTX is $4.42 B
What is the all time high annual EBIT for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual earnings before interest & taxes is $4.44 B
What is Vertex Pharmaceuticals Incorporated annual EBIT year-on-year change?
Over the past year, VRTX annual earnings before interest & taxes has changed by +$136.70 M (+3.19%)
What is Vertex Pharmaceuticals Incorporated quarterly earnings before interest & taxes?
The current quarterly EBIT of VRTX is $1.23 B
What is the all time high quarterly EBIT for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly earnings before interest & taxes is $1.29 B
What is Vertex Pharmaceuticals Incorporated quarterly EBIT year-on-year change?
Over the past year, VRTX quarterly earnings before interest & taxes has changed by +$41.50 M (+3.49%)
What is Vertex Pharmaceuticals Incorporated TTM earnings before interest & taxes?
The current TTM EBIT of VRTX is $298.00 M
What is the all time high TTM EBIT for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM earnings before interest & taxes is $4.81 B
What is Vertex Pharmaceuticals Incorporated TTM EBIT year-on-year change?
Over the past year, VRTX TTM earnings before interest & taxes has changed by -$4.06 B (-93.16%)